"menopause; metabolic syndrome; central obesity; insulin resistance; cardiovascular disease; dyslipidemia; blood pressure"@en . . "5"^^ . . "270351" . . "RIV/00064190:_____/10:#0000025" . "Z(MZ0IKEM2005)" . . . "[E8A336DC2FBF]" . "1"^^ . "Menopause: Clustering of metabolic syndrome components and population changes of insulin resistance." . . "Menopause: Clustering of metabolic syndrome components and population changes of insulin resistance."@en . . . "Menopause: Clustering of metabolic syndrome components and population changes of insulin resistance."@en . . "10"^^ . "RIV/00064190:_____/10:#0000025!RIV10-MZ0-00064190" . . "13" . . "Menopause: Clustering of metabolic syndrome components and population changes of insulin resistance." . "1369-7137" . . . "Lejskov\u00E1, M." . "The aim of the study was to analyze menopausal changes in components of metabolic syndrome (MS) and the parameter of insulin resistance (HOMA-IR). A random population sample of 909 women aged 45\u201354 years was examined. RESULTS The prevalence of MS rose significantly in menopause (REPRO/POSTm 22.9+2.6% /38.3+4.0%; p<0.001). However, a detailed analysis showed among the five components defining MS that increases were only seen in waist circumference (p<0.0001) and triglycerides (p<0.001). A detailed analysis showed an increase in HOMA-IR at levels above the median (REPRO/POSTm: low HOMA-IR 0.9/0.9, ns; high HOMA-IR 1.8/2.1, p<0.001) and an increase in the prevalence of MS just in these high levels of HOMA-IR and those rising during menopause (REPRO/POSTm: low HOMAIR 13.8%/18.7%, ns; high HOMA-IR 30.9%/57.3%, p<0.0001). CONCLUSION The acceleration of MS prevalence at the onset of menopause may be accompanied by an increase in insulin resistance only in the population at highest risk." . . . . "Climacteric" . . . "4" . . "The aim of the study was to analyze menopausal changes in components of metabolic syndrome (MS) and the parameter of insulin resistance (HOMA-IR). A random population sample of 909 women aged 45\u201354 years was examined. RESULTS The prevalence of MS rose significantly in menopause (REPRO/POSTm 22.9+2.6% /38.3+4.0%; p<0.001). However, a detailed analysis showed among the five components defining MS that increases were only seen in waist circumference (p<0.0001) and triglycerides (p<0.001). A detailed analysis showed an increase in HOMA-IR at levels above the median (REPRO/POSTm: low HOMA-IR 0.9/0.9, ns; high HOMA-IR 1.8/2.1, p<0.001) and an increase in the prevalence of MS just in these high levels of HOMA-IR and those rising during menopause (REPRO/POSTm: low HOMAIR 13.8%/18.7%, ns; high HOMA-IR 30.9%/57.3%, p<0.0001). CONCLUSION The acceleration of MS prevalence at the onset of menopause may be accompanied by an increase in insulin resistance only in the population at highest risk."@en . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" .